NOVELLO, Silvia
NOVELLO, Silvia
ONCOLOGIA
"Bad luck" or "science"? This is the dilemma [Article@"Bad luck" or "science"? This is the dylemma]
2015-01-01 Novello, S.
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
2020-01-01 Polverari, Giulia; Ceci, Francesco; Bertaglia, Valentina; Reale, Maria Lucia; Rampado, Osvaldo; Gallio, Elena; Passera, Roberto; Liberini, Virginia; Scapoli, Paola; Arena, Vincenzo; Racca, Manuela; Veltri, Andrea; Novello, Silvia; Deandreis, Désirée
2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer
2015-01-01 Eberhardt W.E.E., De Ruysscher D., Weder W., Le Péchoux C., De Leyn P., Hoffmann H., Westeel V., Stahel R., Felip E., Peters S., Kerr K., Besse B., Vansteenkiste J., Edelman M., Mok T., O'Byrne K., Novello, S., Bubendorf L., Marchetti A., Baas P., Reck M., Syrigos K., Paz-Ares L., Smit E.F., Meldgaard P., Adjei A., Nicolson M., Crinò L., Van Schil P., Senan S., Faivre-Finn C., Rocco G., Veronesi G., Douillard J.-Y., Lim E., Dooms C.
[Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.]
2021-01-01 Esposito, Immacolata; Calabria, Silvia; Piccinni, Carlo; Addesi, Alice; Dondi, Letizia; Ronconi, Giulia; Pedrini, Antonella; Maggioni, Aldo Pietro; Curigliano, Giuseppe; Listi, Angela; Righi, Luisella; Novello, Silvia; Buglioni, Simonetta; Ciliberto, Gennaro; Pruneri, Giancarlo; Martini, Nello
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics
2019-01-01 Ferrer, Léonie; Giaj Levra, Matteo; Brevet, Marie; Antoine, Martine; Mazieres, Julien; Rossi, Giulio; Chiari, Rita; Westeel, Virginie; Poudenx, Michel; Letreut, Jacques; Gervais, Radj; Osman, Giorgia; Girard, Nicolas; Toffart, Anne Claire; Novello, Silvia; Moro-Sibilot, Denis*
A challenge to overcome: the maintenance of the global quality of life in patients with advanced or metastatic non-small cell lung cancer
2016-01-01 Silvia Novello; Simona Carnio
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
2014-01-01 Novello S; Besse B; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I; Scagliotti G; Soria JC
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design
2020-01-01 Passiglia F.; Bironzo P.; Righi L.; Listi A.; Arizio F.; Novello S.; Volante M.; Scagliotti G.V.
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
2006-01-01 CAPPUZZO F ;NOVELLO S ;DE MARINIS F ;SELVAGGI G ;SCAGLIOTTI GV ;BARBIERI F ;MAUR M ;PAPI M ;PASQUINI E ;BARTOLINI S ;MARINI L ;CRINÒ L
A RANDOMIZED PHASE III TRIAL COMPARING STANDARD AND HIGH-DOSE PEMETREXED AS SECOND-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER.
2008-01-01 CULLEN MH; ZATLOUKAL P; SÖRENSON S; S. NOVELLO; FISCHER JR; JOY AA; ZEREU M; PETERSON P; VISSEREN-GRUL CM; ISCOE N
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma
2022-01-01 Tagliamento M.; Bironzo P.; Curcio H.; De Luca E.; Pignataro D.; Rapetti S.G.; Audisio M.; Bertaglia V.; Paratore C.; Bungaro M.; Olmetto E.; Artusio E.; Reale M.L.; Zichi C.; Capelletto E.; Carnio S.; Buffoni L.; Passiglia F.; Novello S.; Scagliotti G.V.; Di Maio M.
A three-week schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: a phase II randomised trial.
2000-01-01 RINALDI M; CRINÒ L; SCAGLIOTTI GV; MOSCONI AM; DEMARINIS F; GRIDELLI C; SELVAGGI G; DELLA GIULIA M; DARWISH S; PORROZZI S; S. NOVELLO; CIPRI A; BARTOLUCCI R; CALANDRI C; TONATO M
Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield
2007-01-01 PRIOLA A.M; PRIOLA S.M; CATALDI A; ERRICO L; DI FRANCO M; CAMPISI P; MOLINARO L; MARCI V; NOVELLO S; C. FAVA
ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINEVINORELBINE IN ADVANCED NON SMALL CELL LUNG CANCER ELDERLY PATIENTS. PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY MILES RANDOMISED TRIAL.
2001-01-01 GRIDELLI C; CIGOLARI S; GALLO C; MANZIONE L; IANNELLO GP; FRONTINI L; FERRAÙ F; S. NOVELLO; PERRONE F; ON BEHALF OF THE MILES INVESTIGATORS
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
2014-01-01 Landi L;Tiseo M;Chiari R;Ricciardi S;Rossi E;Galetta D;Novello S;Milella M;D'Incecco A;Minuti G;Tibaldi C;Salvini J;Facchinetti F;Haspinger ER;Cortinovis D;Santo A;Banna G;Catino A;GiajLevra M;Crinò L;de Marinis F;Cappuzzo F
Actuality and perspective in the medical treatment of non-small cell lung cancer [Article@Attualità e prospettive nella terapia medica del carcinoma polmonare non-a piccole cellule]
2012-01-01 Levra, M.G., Novello, S.
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study
2015-01-01 Barni, Sandro; Maiello, Evaristo; Di Maio, Massimo; Ardizzoni, Andrea; Cappuzzo, Federico; Maranzano, Ernesto; Novello, Silvia; Bennati, Chiara; Ori, Alessandra; Rizzoli, Sara; Crinò, Lucio
Adjuvant chemotherapy after complete resection for early stage NSCLC
2003-01-01 SCAGLIOTTI G ;NOVELLO S
Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
2023-01-01 Petrelli, Fausto; Bertaglia, Valentina; Parati, Maria Chiara; Borgonovo, Karen; De Silva, Pushpamali; Luciani, Andrea; Novello, Silvia; Scartozzi, Mario; Emens, Leisha A; Solinas, Cinzia
Adjuvant chemotherapy in completely resected Non-small cel lung cancer.
2005-01-01 GIORGIO V. SCAGLIOTTI; S. NOVELLO; AND VALTER TORRI
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| "Bad luck" or "science"? This is the dilemma [Article@"Bad luck" or "science"? This is the dylemma] | 2015 | Novello, S. | |
| 18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival | 2020 | Polverari, Giulia; Ceci, Francesco; Bertaglia, Valentina; Reale, Maria Lucia; Rampado, Osvaldo; Gallio, Elena; Passera, Roberto; Liberini, Virginia; Scapoli, Paola; Arena, Vincenzo; Racca, Manuela; Veltri, Andrea; Novello, Silvia; Deandreis, Désirée | |
| 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer | 2015 | Eberhardt W.E.E., De Ruysscher D., Weder W., Le Péchoux C., De Leyn P., Hoffmann H., Westeel V., Stahel R., Felip E., Peters S., Kerr K., Besse B., Vansteenkiste J., Edelman M., Mok T., O'Byrne K., Novello, S., Bubendorf L., Marchetti A., Baas P., Reck M., Syrigos K., Paz-Ares L., Smit E.F., Meldgaard P., Adjei A., Nicolson M., Crinò L., Van Schil P., Senan S., Faivre-Finn C., Rocco G., Veronesi G., Douillard J.-Y., Lim E., Dooms C. | |
| [Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.] | 2021 | Esposito, Immacolata; Calabria, Silvia; Piccinni, Carlo; Addesi, Alice; Dondi, Letizia; Ronconi, Giulia; Pedrini, Antonella; Maggioni, Aldo Pietro; Curigliano, Giuseppe; Listi, Angela; Righi, Luisella; Novello, Silvia; Buglioni, Simonetta; Ciliberto, Gennaro; Pruneri, Giancarlo; Martini, Nello | |
| A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics | 2019 | Ferrer, Léonie; Giaj Levra, Matteo; Brevet, Marie; Antoine, Martine; Mazieres, Julien; Rossi, Giulio; Chiari, Rita; Westeel, Virginie; Poudenx, Michel; Letreut, Jacques; Gervais, Radj; Osman, Giorgia; Girard, Nicolas; Toffart, Anne Claire; Novello, Silvia; Moro-Sibilot, Denis* | |
| A challenge to overcome: the maintenance of the global quality of life in patients with advanced or metastatic non-small cell lung cancer | 2016 | Silvia Novello; Simona Carnio | |
| A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. | 2014 | Novello S; Besse B; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I; Scagliotti G; Soria JC | |
| A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design | 2020 | Passiglia F.; Bironzo P.; Righi L.; Listi A.; Arizio F.; Novello S.; Volante M.; Scagliotti G.V. | |
| A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. | 2006 | CAPPUZZO F ;NOVELLO S ;DE MARINIS F ;SELVAGGI G ;SCAGLIOTTI GV ;BARBIERI F ;MAUR M ;PAPI M ;PASQUINI E ;BARTOLINI S ;MARINI L ;CRINÒ L | |
| A RANDOMIZED PHASE III TRIAL COMPARING STANDARD AND HIGH-DOSE PEMETREXED AS SECOND-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER. | 2008 | CULLEN MH; ZATLOUKAL P; SÖRENSON S; S. NOVELLO; FISCHER JR; JOY AA; ZEREU M; PETERSON P; VISSEREN-GRUL CM; ISCOE N | |
| A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma | 2022 | Tagliamento M.; Bironzo P.; Curcio H.; De Luca E.; Pignataro D.; Rapetti S.G.; Audisio M.; Bertaglia V.; Paratore C.; Bungaro M.; Olmetto E.; Artusio E.; Reale M.L.; Zichi C.; Capelletto E.; Carnio S.; Buffoni L.; Passiglia F.; Novello S.; Scagliotti G.V.; Di Maio M. | |
| A three-week schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer with two different cisplatin dose levels: a phase II randomised trial. | 2000 | RINALDI M; CRINÒ L; SCAGLIOTTI GV; MOSCONI AM; DEMARINIS F; GRIDELLI C; SELVAGGI G; DELLA GIULIA M; DARWISH S; PORROZZI S; S. NOVELLO; CIPRI A; BARTOLUCCI R; CALANDRI C; TONATO M | |
| Accuracy of CT-guided transthoracic needle biopsy of lung lesions: Factors affecting diagnostic yield | 2007 | PRIOLA A.M; PRIOLA S.M; CATALDI A; ERRICO L; DI FRANCO M; CAMPISI P; MOLINARO L; MARCI V; NOVELLO S; C. FAVA | |
| ACTIVITY AND TOXICITY OF GEMCITABINE AND GEMCITABINEVINORELBINE IN ADVANCED NON SMALL CELL LUNG CANCER ELDERLY PATIENTS. PHASE II DATA FROM THE MULTICENTER ITALIAN LUNG CANCER IN THE ELDERLY STUDY MILES RANDOMISED TRIAL. | 2001 | GRIDELLI C; CIGOLARI S; GALLO C; MANZIONE L; IANNELLO GP; FRONTINI L; FERRAÙ F; S. NOVELLO; PERRONE F; ON BEHALF OF THE MILES INVESTIGATORS | |
| Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. | 2014 | Landi L;Tiseo M;Chiari R;Ricciardi S;Rossi E;Galetta D;Novello S;Milella M;D'Incecco A;Minuti G;Tibaldi C;Salvini J;Facchinetti F;Haspinger ER;Cortinovis D;Santo A;Banna G;Catino A;GiajLevra M;Crinò L;de Marinis F;Cappuzzo F | |
| Actuality and perspective in the medical treatment of non-small cell lung cancer [Article@Attualità e prospettive nella terapia medica del carcinoma polmonare non-a piccole cellule] | 2012 | Levra, M.G., Novello, S. | |
| Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study | 2015 | Barni, Sandro; Maiello, Evaristo; Di Maio, Massimo; Ardizzoni, Andrea; Cappuzzo, Federico; Maranzano, Ernesto; Novello, Silvia; Bennati, Chiara; Ori, Alessandra; Rizzoli, Sara; Crinò, Lucio | |
| Adjuvant chemotherapy after complete resection for early stage NSCLC | 2003 | SCAGLIOTTI G ;NOVELLO S | |
| Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis | 2023 | Petrelli, Fausto; Bertaglia, Valentina; Parati, Maria Chiara; Borgonovo, Karen; De Silva, Pushpamali; Luciani, Andrea; Novello, Silvia; Scartozzi, Mario; Emens, Leisha A; Solinas, Cinzia | |
| Adjuvant chemotherapy in completely resected Non-small cel lung cancer. | 2005 | GIORGIO V. SCAGLIOTTI; S. NOVELLO; AND VALTER TORRI |